EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

LIMK1 as a Novel Kinase of β‐Catenin Promotes Esophageal Cancer Metastasis by Cooperating With CDK5

Shu-Jun Li, Zhuo-Ran Liang, Zhi-Chao Liu, Xue-Ping Luo, Jun-Yi Li, Xiao-Mei Yu, Xuan-Zhang Huang, Yan He, Tao-Yang Xu, Jiao-Jiao Xu, Shao-Cong Peng, Yu-Xiang Song und 16 weitere

Advanced Science · 2025

DOI: 10.1002/advs.202503223 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Shu-Jun Li und 27 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Respiratory Disease, Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sci…. Hauptthemen laut MEDLINE: Lim Kinases, Esophageal Neoplasms, beta Catenin, Cyclin-Dependent Kinase 5. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Guangdong Natural Science Research International joint project, Science and Technology Program of Guangzhou.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metastasis is a major cause of cancer deaths, but the underlying molecular mechanisms remain largely unknown. Esophageal squamous cell carcinoma (ESCC) is a highly aggressive cancer with poor survival, yet the key kinases driving ESCC metastasis and their biological function have not been fully discovered. Here, a kinase‐substrate map of metastatic ESCC is presented for the first time by conducting a phosphoproteomics analysis of 60 clinical specimens. By further consolidating data with CRISPR/Cas9 functional screening, LIM domain kinase 1 (LIMK1) is identified as a novel kinase of β‐catenin. The in vitro and in vivo experiments demonstrated that LIMK1 cooperates with Cyclin‐dependent kinase 5 (CDK5) to promote cancer metastasis in a phosphorylation‐dependent manner. Mechanistically, LIMK1 and CDK5 synergistically phosphorylate β‐catenin at S191, enhancing its phosphorylation and interaction with Nucleoporin 93, resulting in β‐catenin nuclear translocation and activation of key pathways in cancer metastasis. High expression of LIMK1 and CDK5 is associated with poor prognosis of ESCC patients, and the clinical and functional significance of LIMK1/CDK5‐Wnt/β‐catenin axis is also verified in esophageal adenocarcinoma, gastric cancer, and lung cancer. Furthermore, the combination of LIMK1 and CDK5 inhibitors significantly suppresses metastasis in multiple models. This work highlights LIMK1 as a novel regulatory and targetable kinase of β‐catenin, informing the treatment of advanced cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lim KinasesEsophageal Neoplasmsbeta CateninCyclin-Dependent Kinase 5Esophageal Squamous Cell CarcinomaHumansMiceAnimalsCell Line, TumorNeoplasm MetastasisPhosphorylationFemaleMale

Stichwörter der Autor:innen

LIMK1esophageal squamous cell carcinomakinase‐substrate mapmetastasisβ‐catenin

Substanzen

Lim Kinasesbeta CateninLIMK1 protein, humanCyclin-Dependent Kinase 5CDK5 protein, humanCTNNB1 protein, human

Autor:innen und Institutionen

  • State Key Laboratory of Respiratory Disease, Guangdong Provincial Key Laboratory of Protein Modification and Degradation, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, 511495, China.
  • State Key Laboratory of Respiratory Disease, Key Laboratory of Biological Targeting Diagnosis, Therapy and Rehabilitation of Guangdong Higher Education Institutes, the Fifth Affiliated Hospital, Guangzhou Medical Univer…
  • State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, The First Affiliated Hospital (College of Clinical Medicine) of Henan Universit…
  • Department of Thoracic Surgery, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200030, China.
  • Department of Thoracic Surgery, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, 511495, China.
  • Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical U…

ORCID-Profile: Bin Li

Förderung

  • National Natural Science Foundation of China
  • Guangdong Natural Science Research International joint project
  • Science and Technology Program of Guangzhou
  • key disciplines of medicine of Guangzhou
  • Guangzhou Education Bureau Yangcheng Scholar Research Project
  • Key Laboratory of Guangdong Higher Education Institutes
  • National Key R&D Program of China
  • Young Talents Program of Sun Yat-sen University Cancer Center

Zitieren

APA

Li, S. J., Liang, Z. R., Liu, Z. C., Luo, X. P., Li, J. Y., Yu, X. M., Huang, X. Z., He, Y., Xu, T. Y., Xu, J. J., Peng, S. C., Song, Y. X., He, Y., Zhuang, X. W., Zheng, C. C., Zhang, F., Lam, A. K., Dai, W., He, M. L., …, & Li, B. (2025). LIMK1 as a Novel Kinase of β‐Catenin Promotes Esophageal Cancer Metastasis by Cooperating With CDK5. Advanced Science. https://doi.org/10.1002/advs.202503223

Vancouver

Li SJ, Liang ZR, Liu ZC, Luo XP, Li JY, Yu XM, et al. LIMK1 as a Novel Kinase of β‐Catenin Promotes Esophageal Cancer Metastasis by Cooperating With CDK5. Advanced Science. 2025. doi:10.1002/advs.202503223

BibTeX
@article{Li2025,
  author = {Li, Shu-Jun and Liang, Zhuo-Ran and Liu, Zhi-Chao and Luo, Xue-Ping and Li, Jun-Yi and Yu, Xiao-Mei and Huang, Xuan-Zhang and He, Yan and Xu, Tao-Yang and Xu, Jiao-Jiao and Peng, Shao-Cong and Song, Yu-Xiang and He, Yan and Zhuang, Xiao-Wan and Zheng, Can-Can and Zhang, Fan and Lam, Alfred King-Yin and Dai, Wei and He, Ming-Liang and Liu, Bo and Zhao, Qi and Lu, Guo-Liang and Liu, Jin-Bao and Wang, Zhen-Ning and Li, Zhi-Gang and Liu, Ze-Xian and Xu, Wen-Wen and Li, Bin},
  title = {LIMK1 as a Novel Kinase of β‐Catenin Promotes Esophageal Cancer Metastasis by Cooperating With CDK5},
  journal = {Advanced Science},
  year = {2025},
  doi = {10.1002/advs.202503223}
}
Kostenlos starten →